Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANTIBIOTICS FOR PREVENTION OF PREMATURE LABOR DUE TO BACTERIAL INFECTIONS

Executive Summary

ANTIBIOTICS FOR PREVENTION OF PREMATURE LABOR DUE TO BACTERIAL INFECTIONS will be the subject of a four-year, $6.8 mil. study coordinated by the Natl. Institute of Child Health & Human Development in collaboration with the Natl. Institute of Allergy & Infectious Diseases. In an Aug. 10 press release announcing the study, HHS explained that women who deliver premature babies are more likely to have certain genitourinary bacterial infections. The study, expected to involve over 15,000 pregnant women, "will determine if these infections cause premature labor and if treatment with antibiotics can prevent early labor from starting," HHS said. Recent studies "indicate that an enzyme, phospholipase A, released in the amniotic membrane surrounding the fetus, may stimulate contractions," HHS noted. The enzyme is also released by the bacteria that cause genitourinary infections. Half of the women in the study will receive an antibiotic, and half a placebo "until the 38th week of pregnancy or delivery, whichever occurs first," HHS said. The research could produce the "first effective method of preventing premature births," according to NICHD Center for Research for Mothers & Children Director Sumner Yaffe. Although the infant mortality rate has declined, the premature birth rate has not decreased in the last 30 years, HHS stated. Clinical trials will be conducted at five university medical centers. The study's principal investigators are: David Eschenbach, University of Washington (Seattle); Ronald Gibbs, University of Texas Health Sciences Center (San Antonio); Stanley James, Columbia University; David Martin, Louisiana State University Medical Center (New Orleans); and Philip Rettig, University of Oklahoma Health Sciences Center (Oklahoma City).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel